Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Emeramide - EmeraMed

Next Previous
Search
Drug Profile

Emeramide - EmeraMed

Alternative Names: Irminix; NBMI

Latest Information Update: 25 Jul 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Kentucky
  • Developer EmeraMed Limited
  • Class Benzene derivatives; Small molecules; Sulfhydryl compounds
  • Mechanism of Action Antioxidants; Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Heavy metal poisoning
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Beta-thalassaemia; Chronic obstructive pulmonary disease; Heavy metal poisoning; Multiple system atrophy; Progressive supranuclear palsy

Most Recent Events

  • 25 Jul 2022 Phase II development is ongoing in Beta-thalassaemia (Treatment-experienced, In the elderly, In adults) in Albania (PO) (NCT04092205)
  • 25 Jul 2022 Phase II development is ongoing in Multiple system atrophy and Progressive supranuclear palsy (In adults, In the elderly) in Slovenia (PO) (NCT04184063)
  • 30 Jun 2021 EmeraMed completes the phase IIa EMERA006 study in Progressive supranuclear palsy (In the elderly, In adults) in Slovenia (PO) (NCT04184063) (EudraCT2018-000506-34)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top